Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728783 | 1.00 | JAK2 (0.56) | JAK2JAK1TYK2PTK2L3MBTL1 | |
| SCHEMBL2762187 | 0.83 | MAPT (0.55) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL2759564 | 0.83 | MAPT (0.46) | JAK2JAK1TYK2PTK2MAPT | |
| SCHEMBL16926556 | 0.82 | JAK2 (0.58) | JAK2JAK1TYK2PIK3C3MAPT | |
| SCHEMBL1505534 | 0.82 | JAK2 (0.61) | JAK2JAK1TYK2GSK3AMAPK10 | |
| SCHEMBL31420515 | 0.82 | JAK2 (0.61) | JAK2JAK1TYK2GSK3AMAPK10 | |
| SCHEMBL19054940 | 0.81 | MAPT (0.43) | JAK2JAK1TYK2MAPTGSK3A | |
| SCHEMBL1437559 | 0.81 | NR3C2 (0.54) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL31420103 | 0.81 | LMNA (0.49) | L3MBTL1MAPTGSK3AMAPK10RIOK2 | |
| SCHEMBL209579 | 0.81 | LMNA (0.49) | L3MBTL1MAPTGSK3AMAPK10RIOK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522583-B2 | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| CN-116891431-A | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| WO-2008003665-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-10 | — | — | WO | disclosed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| CN-1889951-A | Substituted benzazoles and methods of their use as inhibitors of RAF kinase | CHIRON CORP (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1682126-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005037273-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | JAK2 114/4885JAK1 610/4885TYK2 624/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | JAK2 1/4885JAK1 4/4885TYK2 15/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | JAK2 411/4885JAK1 390/4885TYK2 218/4885 |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | BRAF, RAF1, BCOR | JAK2 1262/4885JAK1 1363/4885TYK2 1413/4885 |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | JAK2 393/4885JAK1 351/4885TYK2 453/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | JAK2 1/4885JAK1 4/4885TYK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.